[go: up one dir, main page]

BR9916288A - Clatratos de deidroepiandroesterona e correspondentes composições farmacêuticas - Google Patents

Clatratos de deidroepiandroesterona e correspondentes composições farmacêuticas

Info

Publication number
BR9916288A
BR9916288A BR9916288-1A BR9916288A BR9916288A BR 9916288 A BR9916288 A BR 9916288A BR 9916288 A BR9916288 A BR 9916288A BR 9916288 A BR9916288 A BR 9916288A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
clathrates
dehydroepianderesterone
corresponding pharmaceutical
dehydropianderesterone
Prior art date
Application number
BR9916288-1A
Other languages
English (en)
Inventor
Paolo Corvi Mora
Original Assignee
Euphar Group Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euphar Group Srl filed Critical Euphar Group Srl
Publication of BR9916288A publication Critical patent/BR9916288A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<B>"CLATRATOS DE DEIDROEPIANDROESTERONA E CORRESPONDENTES COMPOSIçõES FARMACêUTICAS"<D> A presente invenção se refere a clatrados de deidropiandroesterona, possivelmente na forma de sulfato, em uma matriz consistindo de uma ciclodextrina e opcionalmente compreendendo um agente de co-solubilização e às correspondentes composições farmacêuticas adequadas para terapia de substituição, para o tratamento de insuficiência adrenocortical.
BR9916288-1A 1998-12-18 1999-12-16 Clatratos de deidroepiandroesterona e correspondentes composições farmacêuticas BR9916288A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998MI002745A IT1304190B1 (it) 1998-12-18 1998-12-18 Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
PCT/EP1999/010010 WO2000037109A2 (en) 1998-12-18 1999-12-16 Clathrates of dehydroepiandrosterone and corresponding pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR9916288A true BR9916288A (pt) 2001-10-16

Family

ID=11381280

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916288-1A BR9916288A (pt) 1998-12-18 1999-12-16 Clatratos de deidroepiandroesterona e correspondentes composições farmacêuticas

Country Status (24)

Country Link
EP (1) EP1140110B1 (pt)
JP (1) JP2002532565A (pt)
KR (1) KR100693514B1 (pt)
CN (1) CN1198620C (pt)
AR (1) AR021663A1 (pt)
AT (1) ATE243517T1 (pt)
AU (1) AU759979B2 (pt)
BR (1) BR9916288A (pt)
CA (1) CA2355148A1 (pt)
CO (1) CO5231137A1 (pt)
DE (1) DE69909128T2 (pt)
DK (1) DK1140110T3 (pt)
EA (1) EA003304B1 (pt)
ES (1) ES2203232T3 (pt)
HU (1) HU225414B1 (pt)
IL (2) IL143776A0 (pt)
IT (1) IT1304190B1 (pt)
NZ (1) NZ512795A (pt)
PE (1) PE20001379A1 (pt)
PT (1) PT1140110E (pt)
TR (1) TR200101766T2 (pt)
TW (1) TWI225791B (pt)
WO (1) WO2000037109A2 (pt)
ZA (1) ZA200105223B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815860B1 (fr) * 2000-10-26 2003-12-12 Oreal Composition, notamment cosmetique, comprenant la dhea et/ou precurseur ou derive de celle-ci et au moins un agent myorelaxant
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
ITMI20021074A1 (it) * 2002-05-20 2003-11-20 Actimex S R L Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
ITMI20022549A1 (it) * 2002-12-02 2004-06-03 Actimex S R L Composizione quaternaria comprendente come sostanza attiva la propolis.
US20070191404A1 (en) * 2004-04-01 2007-08-16 Pierre Bartsch Pharmaceutical compositions of pyrimidine-2,4,6-triones
WO2006137433A1 (ja) * 2005-06-21 2006-12-28 Wakamoto Pharmaceutical Co., Ltd. レボカバスチンを可溶化させた水性薬剤
ITPD20050224A1 (it) * 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
CN103796643B (zh) * 2011-07-19 2016-06-22 潘塔希生物科学股份有限公司 含有脱氢表雄酮(dhea)的片剂
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
WO2014172706A1 (en) * 2013-04-19 2014-10-23 University Of Houston System Cocrystalline dhea formulations
ES2914305T3 (es) * 2017-12-26 2022-06-09 Ind Tech Res Inst Composición para mejorar la solubilidad de sustancias poco solubles, uso de la misma y formulación compleja que contiene la misma
EP3666260A1 (en) 2018-12-13 2020-06-17 Laboratorios Leon Farma SA Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US4978532A (en) * 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US5120720A (en) * 1990-09-20 1992-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Preparation of lipophile:hydroxypropylcyclodextrin complexes by a method using co-solubilizers
WO1994004155A1 (en) * 1992-08-19 1994-03-03 Health Resource Institute, Ltd. Dehydroepiandrosterone therapy for the treatment of eye disorders
WO1995015746A1 (en) * 1993-12-10 1995-06-15 The School Of Pharmacy Liposome delivery systems
EP0866722A1 (en) * 1995-11-13 1998-09-30 Supergen, Inc. Improved formulation for administration of steroid compounds

Also Published As

Publication number Publication date
KR20010086109A (ko) 2001-09-07
IT1304190B1 (it) 2001-03-08
ZA200105223B (en) 2002-09-25
AU1981000A (en) 2000-07-12
CN1198620C (zh) 2005-04-27
HU225414B1 (en) 2006-11-28
JP2002532565A (ja) 2002-10-02
EP1140110B1 (en) 2003-06-25
TR200101766T2 (tr) 2001-12-21
ES2203232T3 (es) 2004-04-01
DK1140110T3 (da) 2003-10-20
PE20001379A1 (es) 2000-11-25
CA2355148A1 (en) 2000-06-29
EP1140110A2 (en) 2001-10-10
AU759979B2 (en) 2003-05-01
DE69909128T2 (de) 2004-05-06
IL143776A0 (en) 2002-04-21
IL143776A (en) 2007-03-08
HUP0104822A3 (en) 2002-08-28
KR100693514B1 (ko) 2007-03-14
DE69909128D1 (de) 2003-07-31
ITMI982745A1 (it) 2000-06-18
PT1140110E (pt) 2003-11-28
AR021663A1 (es) 2002-07-31
TWI225791B (en) 2005-01-01
HUP0104822A2 (hu) 2002-05-29
WO2000037109A2 (en) 2000-06-29
WO2000037109A3 (en) 2000-09-14
CO5231137A1 (es) 2002-12-27
EA003304B1 (ru) 2003-04-24
CN1333686A (zh) 2002-01-30
NZ512795A (en) 2003-08-29
EA200100674A1 (ru) 2001-12-24
ATE243517T1 (de) 2003-07-15

Similar Documents

Publication Publication Date Title
BR9916288A (pt) Clatratos de deidroepiandroesterona e correspondentes composições farmacêuticas
BR122013026957A8 (pt) Dna, vetor de expressão compreendendo o mesmo, fator viii modificado de porcino, seu processo de produção e composição terapêutica compreendendo o mesmo
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
BR0113184A (pt) Implante artificial e processo para produzir o mesmo
ES2187201T3 (es) Empleo de esteroles y de esterolesteres a nanoescala.
ATE357193T1 (de) Bioaktive lasttragende zusammensetzungen zum knochenverbund
WO2001041753A3 (en) Therapeutic compositions and methods for treating periodontitis with antiinflamatory compounds
NZ512692A (en) Sulphoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
BR0107869A (pt) Composições farmacêuticas eletrogiradas
DE50203788D1 (de) Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
BR0107667A (pt) Composto de linezolida em forma de cristal que e farmaceuticamente útil como agente antibacteriano e método de preparação do mesmo
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
BR0012696A (pt) Composição oftálmica
BR0011064A (pt) Processo para a preparação de um poliol, e, composição de poliol
WO2008105808A3 (en) FORMULATIONS OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES
BR0016524A (pt) Suspensão compreendendo oxcarbazepina
BR0309113A (pt) Composições farmacêuticas de liberação controlada de carbidopa e levodopa e processo para a preparação das mesmas
AR047480A1 (es) Composicion para la prevencion y/o tratamiento de enfermedades metabolicas oseas; proceso de preparacion y uso de esta composicion
BR0108405A (pt) Agente de ativação de célula
BR0009778A (pt) Composições antifúngicas de pseudomicina e métodos para utilização das mesmas
BR9906821A (pt) Composição farmacêutica e processo para melhorar a discinesia induzida por levodopa e discinesia tardia, e, uso de riluzol para a preparação de uma composição farmacêutica
AU5685300A (en) Solid preparations containing paroxetine

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.

B15K Others concerning applications: alteration of classification

Ipc: B82Y 5/00 (2011.01), A61K 31/565 (2006.0